Clinical Research Directory
Browse clinical research sites, groups, and studies.
Dose-Painted Intensity Modulated Radiotherapy Pancreas (DP-IMRT Pancreas)
Sponsor: Cancer Trials Ireland
Summary
This is a prospective non-randomised Phase I/II Radiotherapy (RT) study with patients recruited to escalated dose cohorts. Patients with resectable or borderline resectable (per the National Comprehensive Cancer Network (NCCN) criteria) pancreatic adenocarcinoma will receive dose-escalated hypofractionated DP-IMRT via Intensity Modulated Radiotherapy (IMRT) / Volume Modulated Arc Therapy (VMAT).
Official title: DP-IMRT Pancreas: A Non-randomised Phase I/II Study of Dose-escalated Hypofractionated Dose-Painted Intensity Modulated Radiotherapy (DPIMRT) in Resectable/Borderline Resectable Pancreatic Adenocarcinoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
49
Start Date
2024-01-30
Completion Date
2031-07
Last Updated
2025-07-20
Healthy Volunteers
No
Conditions
Interventions
Dose-Painted Intensity Modulated Radiotherapy
Fifteen fractions of external beam radiation therapy (EBRT) delivered via IMRT/ VMAT. Cohort 1 (n = 3-6) Single PTV 40.05 Gy/15#, homogenous dose. Cohort 2 (n = 3-6) High Risk PTV 45 Gy/15# SIB to PTV tumour, Elective PTV 40.05 Gy/15# to nodal regions. Cohort 3 (n = 3-6) High risk PTV 48 Gy/15# SIB to PTV tumour, Elective PTV 40.05 Gy/15# to nodal regions.
Locations (2)
St Luke's Radiation Oncology Network (SLRON)
Dublin, Ireland
St Vincent's University Hospital
Dublin, Ireland